Chapters

Transcript

Video

Reid W. Merryman, MD discusses results of a multicenter phase II trial

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma

Related Presenters

ADVERTISEMENT

Related Videos